Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.

Building on these advances, antibody drug conjugate (ADC) therapy has emerged with worldwide marketing approvals for the indications of breast cancer and lymphoma. An ADC is divided into three ...

ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...

The most advanced, I will say, have to be antibody drug conjugates. At least two of them. One is a HER3 ADC. The other is a TROP2 ADC, has show excellent preliminary data. Potentially can be ...